Literature DB >> 25913799

Colorectal neoplasia in IBD--a single-center analysis of patients undergoing proctocolectomy.

Rüdiger Meyer1, Tilman Laubert, Martin Sommer, Claudia Benecke, Hendrik Lehnert, Klaus Fellermann, Hans-Peter Bruch, Tobias Keck, Christoph Thorns, Jens K Habermann, Jürgen Büning.   

Abstract

PURPOSE: The risk, prevention, and treatment of colorectal neoplasia in inflammatory bowel disease (IBD) are still a matter of debate. The aim of this study was to analyze the occurrence of colorectal neoplasia in IBD patients who underwent proctocolectomy.
METHODS: The study population comprised of 123 IBD patients who underwent proctocolectomy because of neoplasia, therapy refractivity, or complications between January 2000 and July 2011.
RESULTS: One hundred fourteen (92.7%) patients were pre-operatively diagnosed with ulcerative colitis, 5 (4.1%) with colitis indeterminata, and 4 (3.3%) with colonic Crohn's disease. Colectomy was indicated in 39 (31.7%) patients because of a neoplasia, in 68 (55.3%) because of a refractory course of the disease, and in 16 (13.0%) because of complications. Neoplasia was found in 36 patients on a histopathologic evaluation of the colectomy specimens. Ten (8.1%) patients post-operatively showed a pre-operatively not described advanced neoplasia. In three (2.4%) of these patients, the detection of advanced neoplasia (two high-grade intraepithelial neoplasias (IENs), one carcinoma) was a complete de novo finding. Carcinoma had not been diagnosed pre-operatively in six (4.9%) patients. A multifocal distribution of neoplasia was seen in 66.7% of patients with neoplasia. The median duration of disease was 15.5 years in case of neoplasia opposed to 6.0 years in those without neoplasia detection.
CONCLUSION: Our data demonstrate a high rate of pre-operatively undetected high-grade IENs and carcinoma and a frequent multifocal occurrence in IBD patients with long-standing inflammation of the colon. This should be kept in mind for treatment decisions particularly in patients with a chronic refractory course of the disease.

Entities:  

Mesh:

Year:  2015        PMID: 25913799     DOI: 10.1007/s00384-015-2217-7

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  43 in total

1.  High Frequency of Aneuploidy Defines Ulcerative Colitis-Associated Carcinomas: A Prognostic Comparison to Sporadic Colorectal Carcinomas.

Authors:  Marco Gerling; Karl F Meyer; Katrin Fuchs; Bernd W Igl; Britta Fritzsche; Andreas Ziegler; F Bader; Peter Kujath; Hendrik Schimmelpenning; Hans-Peter Bruch; Uwe J Roblick; Jens K Habermann
Journal:  Ann Surg       Date:  2010-07       Impact factor: 12.969

2.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

3.  The European consensus on ulcerative colitis: new horizons?

Authors:  Eduard F Stange; Simon P L Travis
Journal:  Gut       Date:  2008-04-30       Impact factor: 23.059

Review 4.  How reliable/valid is dysplasia in identifying at-risk patients with ulcerative colitis?

Authors:  R H Riddell
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

5.  [Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011].

Authors:  A Dignass; J C Preiss; D E Aust; F Autschbach; A Ballauff; G Barretton; B Bokemeyer; S Fichtner-Feigl; S Hagel; K R Herrlinger; G Jantschek; A Kroesen; W Kruis; T Kucharzik; J Langhorst; M Reinshagen; G Rogler; D Schleiermacher; C Schmidt; S Schreiber; H Schulze; E Stange; M Zeitz; J C Hoffmann; A Stallmach
Journal:  Z Gastroenterol       Date:  2011-08-24       Impact factor: 2.000

6.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

7.  Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years.

Authors:  Tine Jess; Jacob Simonsen; Kristian Tore Jørgensen; Bo Vestergaard Pedersen; Nete Munk Nielsen; Morten Frisch
Journal:  Gastroenterology       Date:  2012-04-19       Impact factor: 22.682

8.  Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted?

Authors:  S R Gorfine; J J Bauer; M T Harris; I Kreel
Journal:  Dis Colon Rectum       Date:  2000-11       Impact factor: 4.585

9.  Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis.

Authors:  W R Connell; J E Lennard-Jones; C B Williams; I C Talbot; A B Price; K H Wilkinson
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

10.  Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis.

Authors:  C N Bernstein; W M Weinstein; D S Levine; F Shanahan
Journal:  Am J Gastroenterol       Date:  1995-12       Impact factor: 10.864

View more
  1 in total

1.  Combining aneuploidy and dysplasia for colitis' cancer risk assessment outperforms current surveillance efficiency: a meta-analysis.

Authors:  Rüdiger Meyer; Sandra Freitag-Wolf; Silke Blindow; Jürgen Büning; Jens K Habermann
Journal:  Int J Colorectal Dis       Date:  2016-10-20       Impact factor: 2.571

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.